<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Oncology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2234-943X</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8965707</article-id>
    <article-id pub-id-type="doi">10.3389/fonc.2022.856988</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Oncology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Xie</surname>
          <given-names>Longxiang</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/654242"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/647946"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yan</surname>
          <given-names>Zhongyi</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/692844"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Han</surname>
          <given-names>Yali</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/704925"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Xiaoyu</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1147005"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Huimin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/760610"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Lu</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/702101"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Li</surname>
          <given-names>Xianzhe</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1702484"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/605469"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Department of Preventive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Software, School of Basic Medical Sciences, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Thoracic Surgery, The Affiliated Nanshi Hospital of Henan University</institution>, <addr-line>Nanyang</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Meng Zhou, Wenzhou Medical University, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Zhihui Liu, Stanford University, United States; Shoukai Kang, University of Washington, United States; Tao Wan, University of Nebraska System, United States; Long-Qi Chen, Sichuan University, China</p>
      </fn>
      <corresp id="fn001">*Correspondence: Xiangqian Guo, <email xlink:href="mailto:xqguo@henu.edu.cn">xqguo@henu.edu.cn</email>; Xianzhe Li, <email xlink:href="mailto:nslxz2007@163.com">nslxz2007@163.com</email>
</corresp>
      <fn fn-type="other" id="fn003">
        <p>†These authors share first authorship</p>
      </fn>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>11</day>
      <month>3</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>856988</elocation-id>
    <history>
      <date date-type="received">
        <day>19</day>
        <month>1</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>2</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Xie, Wang, Yan, Han, Ma, Li, Zhang, Li and Guo</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Xie, Wang, Yan, Han, Ma, Li, Zhang, Li and Guo</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Evaluating the prognostic value of genes of interest in different populations of gastric cancer (GC) is difficult and time-consuming for basic and translational researchers even though many datasets are available in public dataset depositories. In the current study, we developed a robust web-based portal called OSgc (Online consensus Survival analysis of gastric cancer) that enables easy and swift verification of known and novel biomarker candidates in GC. OSgc is composed of gene expression profiling data and clinical follow-up information of 1,824 clinical GC cases, which are collected from 7 public independent datasets derived from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). By OSgc, users input the official gene symbol and will promptly retrieve the Kaplan–Meier survival plot with hazard ratio (HR) and log rank <italic>p</italic> value on the output webpage, by which users could assess the prognostic value of interesting genes for GC patients. Five survival end points containing overall survival, progression-free survival, progression-free interval, relapse-free survival, and disease-free survival could be measured in OSgc. OSgc can greatly help cancer biologists and clinicians to explore the effect of gene expression on patient survival. OSgc is freely available without restrictions at <uri xlink:href="http://bioinfo.henu.edu.cn/GC/GCList.jsp">http://bioinfo.henu.edu.cn/GC/GCList.jsp</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>gastric cancer</kwd>
      <kwd>gene expression</kwd>
      <kwd>GEO</kwd>
      <kwd>OSgc</kwd>
      <kwd>prognostic biomarker</kwd>
      <kwd>survival analysis</kwd>
      <kwd>TCGA</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">
          <institution-wrap>
            <institution>National Natural Science Foundation of China
</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id award-type="contract" rid="cn001">U2004136</award-id>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="4"/>
      <table-count count="2"/>
      <equation-count count="0"/>
      <ref-count count="51"/>
      <page-count count="7"/>
      <word-count count="2832"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Gastric cancer (GC) is the fourth leading factor of cancer mortality in the world. In 2020, GC occurred in 1,089,103 people and resulted in 768,793 deaths. Although there are many advances in treatment of GC, patients have poor prognosis and the 5-year survival rate is just 5%–20%. Prognostic biomarkers can assist clinicians in assessing the risk of clinical outcomes including cancer recurrence or disease progression in the future (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Molecular characteristics such as gene expression and somatic mutations have been reported to represent the primary source of prognostic biomarker (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). A recent study showed that high <italic>SETD2</italic> (SET domain-containing protein 2, also known as <italic>HYPB</italic>) expression was correlated with better prognosis for GC patients, and its overexpression in GC cell lines significantly inhibits cell proliferation, migration, and invasion (<xref rid="B5" ref-type="bibr">5</xref>). Moreover, lower <italic>MTBP</italic> (MDM2-binding protein) expression and <italic>HOXA5</italic> (homeobox A5) expression were significantly associated with longer overall survival time in GC (<xref rid="B6" ref-type="bibr">6</xref>). However, these present retrospective cohort studies were limited to relatively small case series and further validation is required when these findings are going to be translated.</p>
    <p>The expression profiling of gastric cancer has been performed using high-throughput technology such as microarrays and RNA sequencing. These data have been used to measure the association of mRNAs to clinical outcomes in GC patients, while a key step for biomarker development is the biomarker validation in multiple independent cohorts. Even though massive public datasets are available, multistep specialized analyses such as exploring repositories and acquiring and processing data make it difficult for most researchers. Previous studies have reported several good online prognosis tools including PROGgene (<xref rid="B7" ref-type="bibr">7</xref>), PRECOG (<xref rid="B8" ref-type="bibr">8</xref>), OncoLnc (<xref rid="B9" ref-type="bibr">9</xref>), GEPIA (<xref rid="B10" ref-type="bibr">10</xref>), KM plotter (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), and ITTACA (<xref rid="B13" ref-type="bibr">13</xref>), which are available to explore expression changes of individual genes and their association with GC patients’ survival. However, these above tools are restricted regarding low number of clinical cases, lacking most updated data, or login/registering, or limited survival terms.</p>
    <p>Hence, to aid and facilitate the evaluation and verification of prognostic biomarkers in independent cohorts, we developed OSgc, a free and easy-to-use web portal to perform the survival analysis in GC. OSgc is composed of 7 public datasets with available follow-up data for 1,824 GC cases from TCGA and GEO databases, and by which survival analysis can be completed in minutes.</p>
  </sec>
  <sec id="s2">
    <title>Material and Methods</title>
    <sec id="s2_1">
      <title>Data Collection</title>
      <p>Data were collected by searching for keywords related to gastric cancer, clinical outcome, mRNA profiles, and ≥20 samples. The searches were performed in GEO (<uri xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</uri>) and TCGA (<uri xlink:href="https://tcga-data.nci.nih.gov/tcga">https://tcga-data.nci.nih.gov/tcga</uri>). TCGA data are level 3 RNA-Seq data.</p>
    </sec>
    <sec id="s2_2">
      <title>Web Implementation</title>
      <p>The OSgc web portal was set up as we previously developed with minor modification (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). In brief, OSgc contains two main components: storage and data analysis (<xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>). A Java implementation was used to realize OSgc. OSgc used the SQL Server database to provide the storage and management of the gene expression profiles and clinical data for GC and used the Browser/Server architecture network management system to manage the database. R packages including “survminer” and “ggplot2” were used to plot the Kaplan–Meier curves.</p>
      <fig position="float" id="f1">
        <label>Figure 1</label>
        <caption>
          <p>The flowchart of OSgc establishment. GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.</p>
        </caption>
        <graphic xlink:href="fonc-12-856988-g001" position="float"/>
      </fig>
    </sec>
    <sec id="s2_3">
      <title>Searching Previously Reported Prognostic Biomarkers</title>
      <p>A PubMed search was performed to find gastric cancer’s prognostic biomarkers using keywords “gastric cancer,” “stomach cancer,” “adenocarcinoma,” “GC,” “survival,” and “gene expression.” Only studies published in English were encompassed. Eligibility criteria also contained the investigation of the biomarker in &gt;30 patients while biomarkers described only in experimental models or meta-analysis or bioinformatics were excluded.</p>
    </sec>
    <sec id="s2_4">
      <title>Statistical Analysis</title>
      <p>The relationship between clinic-pathological factors and clinical survival outcomes was analyzed by GraphPad Prism 8. R package “survival” was used to perform Cox regression analysis to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs). HR with their corresponding 95% CIs was assessed to explore the prognostic significance of gene of interest in gastric cancer. If a HR is &gt;1 and the 95% CI did not cross 1, the typed gene will show a worse prognosis in the high gene expression group. If a HR is &lt;1 and the 95% CI did not cross 1, it suggests a better prognosis of typed gene in the high gene expression group. Prognostic value was assessed by KM plot analysis and log-rank test. <italic>p</italic> value &lt; 0.05 is regarded as statistically significant.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>Clinical Information of GC Datasets Used in OSgc</title>
      <p>To our knowledge, OSgc provides the largest compilation of expression profiling datasets related to clinical outcomes, comprising 7 datasets and 1,824 clinical GC cases. The median age of these patients is 67 years, and the ratio of male to female is 2.2:1. 1,392 patients have OS, 776 patients have DFS, 420 patients have PFS, and 337 patients have RFS. A summary of above GC cohorts is shown in <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Clinical characteristics of individual dataset in OSgc.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">ID</th>
              <th valign="top" align="center" rowspan="1" colspan="1">GPL</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Sample size</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Gender Female/male</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Number of deaths</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Grade</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Stage (I/II/III/IV)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Median age (years)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Survival terms</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE22377</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL570</td>
              <td valign="top" align="center" rowspan="1" colspan="1">43</td>
              <td valign="top" align="center" rowspan="1" colspan="1">28/15</td>
              <td valign="top" align="center" rowspan="1" colspan="1">30</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2/12/19/2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">64</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, DFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B16" ref-type="bibr">16</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE26253</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL8432</td>
              <td valign="top" align="center" rowspan="1" colspan="1">432</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">68/167/130/67</td>
              <td valign="top" align="center" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B17" ref-type="bibr">17</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE29272</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL96</td>
              <td valign="top" align="center" rowspan="1" colspan="1">126</td>
              <td valign="top" align="center" rowspan="1" colspan="1">27/99</td>
              <td valign="top" align="center" rowspan="1" colspan="1">31</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1/44/81</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5/4/108/8</td>
              <td valign="top" align="center" rowspan="1" colspan="1">59</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B18" ref-type="bibr">18</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE57303</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL570</td>
              <td valign="top" align="center" rowspan="1" colspan="1">70</td>
              <td valign="top" align="center" rowspan="1" colspan="1">14/56</td>
              <td valign="top" align="center" rowspan="1" colspan="1">7</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0/4/34/32</td>
              <td valign="top" align="center" rowspan="1" colspan="1">68</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B19" ref-type="bibr">19</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE62254</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL570</td>
              <td valign="top" align="center" rowspan="1" colspan="1">300</td>
              <td valign="top" align="center" rowspan="1" colspan="1">101/199</td>
              <td valign="top" align="center" rowspan="1" colspan="1">152</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">30/96/95/77</td>
              <td valign="top" align="center" rowspan="1" colspan="1">64</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, DFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B20" ref-type="bibr">20</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE84437</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL6947</td>
              <td valign="top" align="center" rowspan="1" colspan="1">433</td>
              <td valign="top" align="center" rowspan="1" colspan="1">137/296</td>
              <td valign="top" align="center" rowspan="1" colspan="1">209</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">11/38/92/292</td>
              <td valign="top" align="center" rowspan="1" colspan="1">62</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B21" ref-type="bibr">21</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA-GC</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RNAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">420</td>
              <td valign="top" align="center" rowspan="1" colspan="1">134/286</td>
              <td valign="top" align="center" rowspan="1" colspan="1">169</td>
              <td valign="top" align="center" rowspan="1" colspan="1">10/150/251<xref rid="fnT1_1" ref-type="table-fn"><sup>a</sup></xref>
</td>
              <td valign="top" align="center" rowspan="1" colspan="1">55/128/202/40</td>
              <td valign="top" align="center" rowspan="1" colspan="1">67</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, RFS, PFI, PFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B20" ref-type="bibr">20</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Total</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">1824</td>
              <td valign="top" align="center" rowspan="1" colspan="1">441/951</td>
              <td valign="top" align="center" rowspan="1" colspan="1">598</td>
              <td valign="top" align="center" rowspan="1" colspan="1">11/194/332</td>
              <td valign="top" align="center" rowspan="1" colspan="1">171/593/677/519</td>
              <td valign="top" align="center" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="fnT1_1">
            <label>a</label>
            <p>9 samples were GX that grade cannot be defined.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>To explore the relationship between clinical characteristics and outcomes, we performed Kaplan–Meier plots for GC patients stratified by TNM stage and gender in datasets used for OSgc (<xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>). In these patients, TNM stage was significantly related with OS (<italic>p</italic> &lt; 0.0001) and DFS (<italic>p</italic> &lt; 0.0001), as we knew (<xref rid="B22" ref-type="bibr">22</xref>). Nevertheless, gender showed no significant association with OS (<italic>p</italic> = 0.4939) and DFS (<italic>p</italic> = 0.7764).</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>The association of GC patient survival with gender <bold>(A, B)</bold> and stage <bold>(C, D)</bold> in OSgc.</p>
        </caption>
        <graphic xlink:href="fonc-12-856988-g002" position="float"/>
      </fig>
    </sec>
    <sec id="s3_2">
      <title>Web Interface</title>
      <p>As shown in <xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>, OSgc could be easily used by typing only the gene symbol and selecting the individual/combined cohort, stage, gender, grade, and age on the input webpage. After then, “Kaplan–Meier plot” is clicked, and the survival outcome plots will be shown up on the output webpage in less than a minute (might vary if advanced plots are selected). Furthermore, users can easily obtain KM plots for multiple genes (with maximum 5 genes).</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>An overview of OSgc application. OSgc application mainly contains three sections including input, clinical features, and results.</p>
        </caption>
        <graphic xlink:href="fonc-12-856988-g003" position="float"/>
      </fig>
    </sec>
    <sec id="s3_3">
      <title>Validation and Application</title>
      <p>To assess the capabilities of OSgc in the evaluation of prognostic biomarkers, we collected 20 previously published GC prognostic biomarkers through PubMed search (shown in <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). These published prognostic biomarkers include 16 unfavorable and 4 favorable prognostic biomarkers which have been verified by tissue-based immunohistochemistry (IHC), Western blot, and RT-PCR in literatures. To test these published prognostic biomarkers in OSgc, OS or DFS was selected as survival term in the combined datasets in OSgc. Combined datasets mean that each cohort was divided separately into strata by selecting the proper cutoff value, which are then put together for survival analysis. The hazard ratio and <italic>p</italic> value in original studies and OSgc are given in <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>. The test results showed that the prognostic values of 17 genes line up with previous reports, while 3 genes did not reach significance in OSgc.</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Test the performance of previously reported prognostic biomarker candidates using OSgc.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Gene symbol<xref rid="fnT2_1" ref-type="table-fn"><sup>a</sup></xref>
</th>
              <th valign="top" colspan="5" align="center" rowspan="1">Literature data</th>
              <th valign="top" colspan="4" align="center" rowspan="1">OSgc data</th>
            </tr>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">N</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Survival</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Prognostic value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Method</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Dataset</th>
              <th valign="top" align="center" rowspan="1" colspan="1">HR (95% CI)</th>
              <th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic> value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Validation results</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">HOXA5</td>
              <td valign="top" align="center" rowspan="1" colspan="1">30</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and Western blot</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B23" ref-type="bibr">23</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3724 (1.114–1.5818)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0015</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CAP2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">436</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B24" ref-type="bibr">24</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5207 (1.2645–1.7858)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">LAMA4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">388</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B25" ref-type="bibr">25</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4904 (1.2305–1.8053)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">MTBP</td>
              <td valign="top" align="center" rowspan="1" colspan="1">352</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and Western blot</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B6" ref-type="bibr">6</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE22377</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.7219 (1.2506–5.9242)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0116</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">RAI14</td>
              <td valign="top" align="center" rowspan="1" colspan="1">68</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B26" ref-type="bibr">26</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6117 (1.3304–1.9524)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SETD2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">153</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Favorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B5" ref-type="bibr">5</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.6946 (1.3304–1.0078)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0603</td>
              <td valign="top" align="center" rowspan="1" colspan="1">×</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">NDRG4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">286</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B27" ref-type="bibr">27</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4149 (1.1904–1.6818)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPARC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">227</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B28" ref-type="bibr">28</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4217 (1.1612–1.7407)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">7e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">HOXB9</td>
              <td valign="top" align="center" rowspan="1" colspan="1">190</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Favorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B29" ref-type="bibr">29</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.8461 (0.7008–1.0215)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0821</td>
              <td valign="top" align="center" rowspan="1" colspan="1">×</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DDC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">39</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Favorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B30" ref-type="bibr">30</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE22377</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.2805 (0.097–0.8108)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0189</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">ERCC1</td>
              <td valign="top" align="center" rowspan="1" colspan="1">106</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B31" ref-type="bibr">31</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE62254</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6054 (1.1377–2.2662)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.007</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">STAT3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">50</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RT-PCR, Western blot and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B32" ref-type="bibr">32</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA<break/>GSE22377</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4306 (1.0138–2.0188)<break/>3.0762 (1.4271–6.6306)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0416<break/>0.0041</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">IGFBP7</td>
              <td valign="top" align="center" rowspan="1" colspan="1">247</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B33" ref-type="bibr">33</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4577 (1.2253–1.7342)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TIMP3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">17</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B34" ref-type="bibr">34</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4779 (1.2283–1.7783)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">KLK6</td>
              <td valign="top" align="center" rowspan="1" colspan="1">66</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR and IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B35" ref-type="bibr">35</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE62254</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4878 (1.0523–2.1037)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0246</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">NNMT</td>
              <td valign="top" align="center" rowspan="1" colspan="1">641</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B36" ref-type="bibr">36</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3734 (1.1529–1.6362)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">ATAD2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">166</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B37" ref-type="bibr">37</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE22377</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.4084 (1.5908–7.3027)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0016</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CXCR3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">96</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Favorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RT-PCR and qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B38" ref-type="bibr">38</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.7203 (0.5923–0.8759)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0010</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SMYD3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">166</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IHC</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B39" ref-type="bibr">39</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1857 (0.9798–1.435)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0801</td>
              <td valign="top" align="center" rowspan="1" colspan="1">×</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">S100A4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">434</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Unfavorable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">qRT-PCR</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B40" ref-type="bibr">40</xref>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2081 (1.0103–1.4447)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0382</td>
              <td valign="top" align="center" rowspan="1" colspan="1">√</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="fnT2_1">
            <label>a</label>
            <p>HOXA5, homeobox A5; CAP2, cyclase-associated protein 2; LAMA4, laminin a4; MTBP, MDM2 binding protein; RAI14, retinoic acid induced 14; SETD2, SET domain containing; NDRG4, N-Myc downstream-regulated gene 4; SPARC: secreted protein acidic and rich in cysteine; HOXB9: homeodomain-containing transcription factor; DDC: Dopa decarboxylase; ERCC1, excision repair cross complementation group 1; STAT3, signal transducers and activators of transcription; IGFBP7, insulin-like growth factor binding protein 7; KLK6, kallikrein 6; NNMT, nicotinamide N-methyltransferase; ATAD2, ATPase family, AAA domain containing 2; CXCR3, chemokine receptor; SMYD3, MYND domain-containing protein 3; S100A4: S100 calcium binding protein A4.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="s3_4">
      <title>Comprehensive Analysis of the Prognosis Significance of E2Fs by OSgc</title>
      <p>Increasing evidence has indicated that E2Fs, a family of critical transcription factors that regulate cell cycle progression and other cellular processes, are aberrantly expressed and involved in the tumor progression in various malignant tumors (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Recently, four research groups had systematically studied the expression patterns and prognostic values of eight E2Fs in patients with breast cancer (BC) (<xref rid="B43" ref-type="bibr">43</xref>), ovarian cancer (OC) (<xref rid="B44" ref-type="bibr">44</xref>), hepatocellular carcinoma (HCC) (<xref rid="B45" ref-type="bibr">45</xref>), and lung carcinoma (<xref rid="B46" ref-type="bibr">46</xref>) by investigating a series of databases. For example, Huang et al. had shown that high expression of individual <italic>E2Fs</italic> was related with poor prognosis in HCC patients (<xref rid="B45" ref-type="bibr">45</xref>). However, the expression and prognostic significance of each E2F in gastric cancer have not yet been elucidated. Herein, we can easily explore the prognostic significance for all <italic>E2F</italic> members in GC by using web tool OSgc. The results showed that the higher transcriptional levels of both <italic>E2F2</italic> and <italic>E2F8</italic> were associated with better overall survival in gastric cancer patients (<xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref>). However, other E2Fs members were not significantly correlated with OS of GC patients (data not shown).</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>The prognostic value of E2F2 and E2F8 in GC patients (OS in OSgc). <bold>(A)</bold> KM survival plot for E2F2 suggests that its high expression (red) indicates favorable prognosis (GC patients were separated by the quarter of gene expression level); <bold>(B)</bold> KM survival plot for E2F8 suggests that its high expression (red) indicates favorable prognosis (GC patients were separated by the quarter of gene expression level); E2F2, E2F transcription factor 2; E2F8, E2F transcription factor 8; GC, gastric cancer; OS, overall survival.</p>
        </caption>
        <graphic xlink:href="fonc-12-856988-g004" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>Prognostic biomarkers are an important supplement to traditional clinical and histopathological features, for example, tumor size and lymph node metastasis, which cannot completely predict the prognosis of patients with cancer. The development of biomarkers by genomic, transcriptomic, and proteomic methods holds the promise of “individualized medicine,” bringing a new ground-breaking point to disease diagnosis, classification, and prognosis. The gene expression profiling datasets in TCGA and GEO are of great value in deepening our understanding of the underlying molecular mechanisms involved in GC, as well as in the identification of novel diagnostic and prognostic biomarkers (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). For the maximum utilization of GEO and TCGA data resources, it is very necessary to provide a web-based portal that allows clinicians and cancer biologists (regardless of having bioinformatics background or not) to easily access, analyze, and visualize the data. To identify genes related with patient survival is one possible way to prioritize genes with oncogenic or tumor-suppressor properties for further study. The user-friendly web portal of OSgc promotes the gene identification for survival associations in GC. Compared with published survival web tools such as OncoLnc (<xref rid="B9" ref-type="bibr">9</xref>), GEPIA (<xref rid="B10" ref-type="bibr">10</xref>), and KM plotter (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), GEPIA and KM plotters are good in performing an extensive survey of prognosis in general cancer types; however, it has limited cases of GC (GEPIA contains 375 patients from TCGA; KM plotter includes 1,440 cases from TCGA and GEO). OncoLnc only containing TCGA data was developed to assess the prognostic significance of non-coding genes. More importantly, OSgc has integrated seven GC cohorts and incorporated the clinical covariates to provide more informative survival plots to the researchers.</p>
    <p>We have demonstrated here the usefulness of OSgc using 20 previously published prognostic biomarkers as examples for rapid survival analysis. 85% (17 of 20) of these reported prognostic biomarkers were confirmed to be prognostically significant in OSgc. The three genes without statistical significance in OSgc could be due to several factors including different detecting methods (the analysis method for the <italic>HOXBP</italic> and <italic>SMYD3</italic> prognosis study was IHC) and starting material (the material for <italic>SETD2</italic> prognosis study was paraffin-embedded FFPE tissues). Moreover, we used OSgc to quickly systematically analyze the potential prognostic values of <italic>E2F</italic> family members and found that both <italic>E2F2</italic> and <italic>E2F8</italic> are favorable prognostic biomarkers for GC patients. Previous studies indicated that E2F2 exhibited as a tumor suppressor in epithelial tissues (<xref rid="B49" ref-type="bibr">49</xref>) or Myc-induced T cell lymphomagenesis (<xref rid="B50" ref-type="bibr">50</xref>), and overexpression of E2F2 inhibited the progression of these tumors. E2F8 is also a critical tumor suppressor for postnatal liver development (<xref rid="B51" ref-type="bibr">51</xref>). Compared with other web tools, OSgc is a free tool with the largest number of gastric cancers to perform the survival analysis based on gene expression. In the future, we will check whether the new standard datasets (including gene expression profile and clinical survival information) from different databases (such as TCGA, GEO and ArrayExpress) come out every 3 months, then we will incorporate these new gene expression profiles as well as additional utilities which are suggested by the users.</p>
    <p>All in all, OSgc is a free and easy-to-use web portal to assess the performance of potential prognostic biomarkers for gastric cancer.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.</p>
  </sec>
  <sec sec-type="author-contributions" id="s6">
    <title>Author Contributions</title>
    <p>XG, XL: study concept and design. LX, QW, ZY: acquisition of data. QW, LX, YH, HL, LZ: analysis and interpretation of data. LX, QW, ZY, XG, XL: draft of the manuscript. XG, LX, QW, ZY, XL: critical revision of the manuscript for intellectual content. All authors contributed to the article and approved the submitted version.</p>
  </sec>
  <sec sec-type="funding-information" id="s7">
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China (No. U2004136), supporting program for Central Plain Young Top Talents (ZYQR201912176), Kaifeng Science and technology development Plan (2103005) program from the Academy for Advanced Interdisciplinary Studies of Henan University (Y21008L).</p>
  </sec>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s9">
    <title>Publisher’s Note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
</body>
<back>
  <sec id="s10">
    <title>Abbreviations</title>
    <p>GC, gastric cancer; GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; SETD2, SET domain-containing protein 2; BC, breast cancer; OC, ovarian cancer; HCC, hepatocellular carcinoma; LUCA, lung carcinoma.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens</surname><given-names>N</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name></person-group>. <article-title>Cancer Biomarker Discovery and Validation</article-title>. <source>Transl Cancer Res</source> (<year>2015</year>) <volume>4</volume>:<page-range>256–69</page-range>. doi: <pub-id pub-id-type="doi">10.3978/j.issn.2218-676X.2015.06.04</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Chao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Systemic Analysis of the Expression and Prognostic Significance of PAKs in Breast Cancer</article-title>. <source>Genomics</source> (<year>2020</year>) <volume>112</volume>(<issue>3</issue>):<page-range>2433–44</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ygeno.2020.01.016</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients</article-title>. <source>Genes</source> (<year>2019</year>) <volume>10</volume>:<fpage>36</fpage>. doi: <pub-id pub-id-type="doi">10.3390/genes10010036</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Luan</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group>. <article-title>The Translational Values of TRIM Family in Pan-Cancers: From Functions and Mechanisms to Clinics</article-title>. <source>Pharmacol Ther</source> (<year>2021</year>) <volume>227</volume>:<fpage>107881</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107881</pub-id>
<pub-id pub-id-type="pmid">33930453</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Raghoonundun</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>SETD2 Indicates Favourable Prognosis in Gastric Cancer and Suppresses Cancer Cell Proliferation, Migration, and Invasion</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2018</year>) <volume>498</volume>(<issue>3</issue>):<page-range>579–85</page-range>. S0006291X18304960. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.03.022</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>MDM2 Binding Protein as a Predictor of Metastasis and a Novel Prognostic Biomarker in Patients With Gastric Cancer</article-title>. <source>Oncol Lett</source> (<year>2017</year>) <volume>14</volume>:<page-range>6409–16</page-range>. doi: <pub-id pub-id-type="doi">10.3892/ol.2017.7031</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>CP</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name></person-group>. <article-title>PROGgeneV2: Enhancements on the Existing Database</article-title>. <source>BMC Cancer</source> (<year>2014</year>) <volume>14</volume>:<fpage>970</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2407-14-970</pub-id>
<pub-id pub-id-type="pmid">25518851</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Bratman</surname><given-names>SV</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The Prognostic Landscape of Genes and Infiltrating Immune Cells Across Human Cancers</article-title>. <source>Nat Med</source> (<year>2015</year>) <volume>21</volume>:<page-range>938–45</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.3909</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anaya</surname><given-names>J</given-names></name></person-group>. <article-title>OncoLnc: Linking TCGA Survival Data to mRNAs, miRNAs, and lncRNAs</article-title>. <source>PeerJ Comput Sci</source> (<year>2016</year>) <volume>2</volume>:<elocation-id>e67</elocation-id>. doi: <pub-id pub-id-type="doi">10.7717/peerj-cs.67</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses</article-title>. <source>Nucleic Acids Res</source> (<year>2017</year>) <volume>45</volume>(<issue>W1</issue>):<fpage>W98</fpage>–<lpage>W102</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id>
<pub-id pub-id-type="pmid">28407145</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szász</surname><given-names>AM</given-names></name><name><surname>Lánczky</surname><given-names>A</given-names></name><name><surname>Nagy</surname><given-names>Á</given-names></name><name><surname>Förster</surname><given-names>S</given-names></name><name><surname>Hark</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Cross-Validation of Survival Associated Biomarkers in Gastric Cancer Using Transcriptomic Data of 1,065 Patients</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>:<page-range>49322–33</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.10337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Győrffy</surname><given-names>B</given-names></name><name><surname>Surowiak</surname><given-names>P</given-names></name><name><surname>Budczies</surname><given-names>J</given-names></name><name><surname>Lánczky</surname><given-names>A</given-names></name></person-group>. <article-title>Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>e82241</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0082241</pub-id>
<pub-id pub-id-type="pmid">24367507</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elfilali</surname><given-names>A</given-names></name><name><surname>Lair</surname><given-names>S</given-names></name><name><surname>Verbeke</surname><given-names>C</given-names></name><name><surname>Rosa</surname><given-names>PL</given-names></name><name><surname>Radvanyi</surname><given-names>F</given-names></name><name><surname>Barillot</surname><given-names>E</given-names></name></person-group>. <article-title>ITTACA: A New Database for Integrated Tumor Transcriptome Array and Clinical Data Analysis</article-title>. <source>Nucleic Acids Res</source> (<year>2006</year>) <volume>34</volume>:<page-range>D613–6</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkj022</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>OSkirc: A Web Tool for Identifying Prognostic Biomarkers in Kidney Renal Clear Cell Carcinoma</article-title>. <source>Future Oncol (London England)</source> (<year>2019</year>) <volume>15</volume>:<page-range>3103–10</page-range>. doi: <pub-id pub-id-type="doi">10.2217/fon-2019-0296</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Nan</surname><given-names>F</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>OSacc: Gene Expression-Based Survival Analysis Web Tool For Adrenocortical Carcinoma</article-title>. <source>Cancer Manag Res</source> (<year>2019</year>) <volume>11</volume>:<page-range>9145–52</page-range>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S215586</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Förster</surname><given-names>S</given-names></name><name><surname>Gretschel</surname><given-names>S</given-names></name><name><surname>Jöns</surname><given-names>T</given-names></name><name><surname>Yashiro</surname><given-names>M</given-names></name><name><surname>Kemmner</surname><given-names>W</given-names></name></person-group>. <article-title>THBS4, a Novel Stromal Molecule of Diffuse-Type Gastric Adenocarcinomas, Identified by Transcriptome-Wide Expression Profiling</article-title>. <source>Mod Pathol</source> (<year>2011</year>) <volume>24</volume>:<fpage>1390</fpage>. doi: <pub-id pub-id-type="doi">10.1038/modpathol.2011.99</pub-id>
<pub-id pub-id-type="pmid">21701537</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sohn</surname><given-names>I</given-names></name><name><surname>Do</surname><given-names>I-G</given-names></name><name><surname>Kim</surname><given-names>K-M</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><etal/></person-group>. <article-title>Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients After Surgery</article-title>. <source>PloS One</source> (<year>2014</year>) <volume>9</volume>:<elocation-id>e90133</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0090133</pub-id>
<pub-id pub-id-type="pmid">24598828</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname><given-names>F</given-names></name><name><surname>Laganière</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>AW</given-names></name><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Alagappan</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations</article-title>. <source>Cell</source> (<year>2011</year>) <volume>146</volume>:<page-range>318–31</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.06.019</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Whole Genome Gene Copy Number Profiling of Gastric Cancer Identifies PAK1 and KRAS Gene Amplification as Therapy Targets</article-title>. <source>Genes Chromosomes Cancer</source> (<year>2014</year>) <volume>53</volume>:<page-range>883–94</page-range>. doi: <pub-id pub-id-type="doi">10.1002/gcc.22196</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristescu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>K-M</given-names></name><name><surname>Ting</surname><given-names>JC</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Molecular Analysis of Gastric Cancer Identifies Subtypes Associated With Distinct Clinical Outcomes</article-title>. <source>Nat Med</source> (<year>2015</year>) <volume>21</volume>:<page-range>449–56</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.3850</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Predictive Test for Chemotherapy Response in Resectable Gastric Cancer: A Multi-Cohort, Retrospective Analysis</article-title>. <source>Lancet Oncol</source> (<year>2018</year>) <volume>19</volume>:<fpage>629</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30108-6</pub-id>
<pub-id pub-id-type="pmid">29567071</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravalos</surname><given-names>C</given-names></name><name><surname>Jimeno</surname><given-names>A</given-names></name></person-group>. <article-title>HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target</article-title>. <source>Ann Oncol</source> (<year>2008</year>) <volume>19</volume>:<page-range>1523–9</page-range>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdn169</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name></person-group>. <article-title>HOXA5 Inhibits Tumor Growth of Gastric Cancer Under the Regulation of microRNA-196a</article-title>. <source>Gene</source> (<year>2019</year>) <volume>681</volume>:<page-range>62–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.gene.2018.09.051</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>LQ</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name></person-group>. <article-title>CAP2 is a Valuable Biomarker for Diagnosis and Prognostic in Patients With Gastric Cancer</article-title>. <source>Pathol Oncol Res</source> (<year>2018</year>) <volume>26</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12253-018-0450-4</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qinge</surname><given-names>H</given-names></name><name><surname>Xinling</surname><given-names>Z</given-names></name></person-group>. <article-title>LAMA4 Expression is Activated by Zinc Finger E?box?binding Homeobox?1 and Independently Predicts Poor Overall Survival in Gastric Cancer</article-title>. <source>Oncol Rep</source> (<year>2018</year>) <volume>40</volume>(<issue>3</issue>):<page-range>1725–33</page-range>. doi: <pub-id pub-id-type="doi">10.3892/or.2018.6564</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>ZQ</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name></person-group>. <article-title>High Expression of Retinoic Acid Induced 14 (RAI14) in Gastric Cancer and Its Prognostic Value</article-title>. <source>Med Sci Monit</source> (<year>2018</year>) <volume>24</volume>:<fpage>2244</fpage>. doi: <pub-id pub-id-type="doi">10.12659/MSM.910133</pub-id>
<pub-id pub-id-type="pmid">29654694</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>She</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>NDRG4 in Gastric Cancer Determines Tumor Cell Proliferation and Clinical Outcome</article-title>. <source>Mol Carcinog</source> (<year>2018</year>) <volume>57</volume>(<issue>6</issue>):<page-range>762–71</page-range>. doi: <pub-id pub-id-type="doi">10.1002/mc.22798</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutomu</surname><given-names>S</given-names></name><name><surname>Takashi</surname><given-names>O</given-names></name><name><surname>Naoto</surname><given-names>Y</given-names></name><name><surname>Takanobu</surname><given-names>Y</given-names></name><name><surname>Shinichi</surname><given-names>H</given-names></name><name><surname>Norio</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical Significance of SPARC Gene Expression in Patients With Gastric Cancer</article-title>. <source>J Surg Oncol</source> (<year>2013</year>) <volume>108</volume>:<page-range>364–8</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jso.23425</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Decreased Expression of HOXB9 is Related to Poor Overall Survival in Patients With Gastric Carcinoma</article-title>. <source>Dig Liver Dis</source> (<year>2013</year>) <volume>45</volume>:<page-range>422–9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.dld.2012.12.004</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florou</surname><given-names>D</given-names></name><name><surname>Fragoulis</surname><given-names>EG</given-names></name><name><surname>Scorilas</surname><given-names>A</given-names></name><name><surname>Papadopoulos</surname><given-names>IN</given-names></name></person-group>. <article-title>L-Dopa Decarboxylase (DDC) Constitutes an Emerging Biomarker in;Predicting Patients' Survival With Stomach Adenocarcinomas</article-title>. <source>J Cancer Res Clin Oncol</source> (<year>2013</year>) <volume>139</volume>:<fpage>297</fpage>–<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00432-012-1326-8</pub-id>
<pub-id pub-id-type="pmid">23064786</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiuhua</surname><given-names>D</given-names></name><name><surname>Haihong</surname><given-names>Y</given-names></name><name><surname>Yongping</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>G</given-names></name><name><surname>Ping</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prognostic Value of ERCC1 mRNA Expression in non-Small Cell Lung Cancer, Breast Cancer, and Gastric Cancer in Patients From Southern China</article-title>. <source>Int J Clin Exp Pathol</source> (<year>2014</year>) <volume>7</volume>:<page-range>8312–21</page-range>.</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Overexpression of SMYD3 was Associated With Increased STAT3 Activation in Gastric Cancer</article-title>. <source>Med Oncol</source> (<year>2015</year>) <volume>32</volume>:<fpage>1</fpage>–<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12032-014-0404-y</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Decreased Expression of IGFBP7 was a Poor Prognosis Predictor for Gastric Cancer Patients</article-title>. <source>Tumor Biol</source> (<year>2014</year>) <volume>35</volume>:<page-range>8875–81</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s13277-014-2160-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Peña</surname><given-names>S</given-names></name><name><surname>Sampieri</surname><given-names>CL</given-names></name><name><surname>Ochoa-Lara</surname><given-names>M</given-names></name><name><surname>León-Córdoba</surname><given-names>K</given-names></name><name><surname>Remes-Troche</surname><given-names>JM</given-names></name></person-group>. <article-title>Expression of the Matrix Metalloproteases 2, 14, 24, and 25 and Tissue Inhibitor 3 as Potential Molecular Markers in Advanced Human Gastric Cancer</article-title>. <source>Dis Markers</source> (<year>2014</year>) <volume>2014</volume>:<fpage>285906</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2014/285906</pub-id>
<pub-id pub-id-type="pmid">24669030</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hisashi</surname><given-names>N</given-names></name><name><surname>Koshi</surname><given-names>M</given-names></name><name><surname>Tohru</surname><given-names>U</given-names></name><name><surname>Barnard</surname><given-names>GF</given-names></name><name><surname>Masaichi</surname><given-names>O</given-names></name><name><surname>Kosei</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer</article-title>. <source>Clin Cancer Res</source> (<year>2005</year>) <volume>11</volume>:<page-range>6800–6</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0943</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Yong</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Nicotinamide N-Methyltransferase: A Potential Biomarker for Worse Prognosis in Gastric Carcinoma</article-title>. <source>Am J Cancer Res</source> (<year>2016</year>) <volume>6</volume>:<fpage>649</fpage>.<pub-id pub-id-type="pmid">27152242</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MJ</given-names></name><name><surname>Zhang</surname><given-names>CZ</given-names></name><name><surname>Du</surname><given-names>WJ</given-names></name><name><surname>Yang</surname><given-names>XZ</given-names></name><name><surname>Chen</surname><given-names>ZP</given-names></name></person-group>. <article-title>ATAD2 is Overexpressed in Gastric Cancer and Serves as an Independent Poor Prognostic Biomarker</article-title>. <source>Clin Transl Oncol</source> (<year>2015</year>) <volume>18</volume>:<fpage>1</fpage>–<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12094-015-1430-8</pub-id>
<pub-id pub-id-type="pmid">26169213</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Maskey</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>Overexpression of the Chemokine Receptor CXCR3 and its Correlation With Favorable Prognosis in Gastric Cancer</article-title>. <source>Hum Pathol</source> (<year>2015</year>) <volume>46</volume>(<issue>12</issue>):<page-range>1872–80</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.humpath.2015.08.004</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>F</given-names></name><name><surname>Xin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated With Overexpression of Transforming Growth Factor-β1 in Gastric Cancer</article-title>. <source>J Am Coll Surg</source> (<year>2015</year>) <volume>221</volume>:<page-range>579–90</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2015.02.023</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Ye</surname><given-names>ZZ</given-names></name></person-group>. <article-title>High-Level Expression of S100A4 Correlates With Lymph Node Metastasis and Poor Prognosis in Patients With Gastric Cancer</article-title>. <source>Ann Surg Oncol</source> (<year>2010</year>) <volume>17</volume>:<fpage>89</fpage>–<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1245/s10434-009-0722-z</pub-id>
<pub-id pub-id-type="pmid">19820999</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimarchi</surname><given-names>JM</given-names></name><name><surname>Lees</surname><given-names>JA</given-names></name></person-group>. <article-title>Sibling Rivalry in the E2F Family</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2002</year>) <volume>3</volume>:<fpage>11</fpage>–<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrm714</pub-id>
<pub-id pub-id-type="pmid">11823794</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui-Zi</surname><given-names>C</given-names></name><name><surname>Shih-Yin</surname><given-names>T</given-names></name><name><surname>Gustavo</surname><given-names>L</given-names></name></person-group>. <article-title>Emerging Roles of E2Fs in Cancer: An Exit From Cell Cycle Control</article-title>. <source>Nat Rev Cancer</source> (<year>2009</year>) <volume>9</volume>:<fpage>785</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrc2696</pub-id>
<pub-id pub-id-type="pmid">19851314</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xiang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Expression Patterns of E2F Transcription Factors and Their Potential Prognostic Roles in Breast Cancer</article-title>. <source>Oncol Lett</source> (<year>2018</year>) <volume>15</volume>:<page-range>9216–30</page-range>. doi: <pub-id pub-id-type="doi">10.3892/ol.2018.8514</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Zuo</surname><given-names>M-Z</given-names></name></person-group>. <article-title>E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer</article-title>. <source>Front Oncol</source> (<year>2019</year>) <volume>9</volume>:<elocation-id>161</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2019.00161</pub-id>
<pub-id pub-id-type="pmid">30967995</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y-L</given-names></name><name><surname>Ning</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>L-B</given-names></name><name><surname>Lian</surname><given-names>Y-F</given-names></name><name><surname>Gu</surname><given-names>Y-R</given-names></name><name><surname>Wang</surname><given-names>J-L</given-names></name><etal/></person-group>. <article-title>Promising Diagnostic and Prognostic Value of E2Fs in Human Hepatocellular Carcinoma</article-title>. <source>Cancer Manag Res</source> (<year>2019</year>) <volume>11</volume>:<fpage>1725</fpage>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S182001</pub-id>
<pub-id pub-id-type="pmid">30863181</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C-C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S-J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Z-L</given-names></name><etal/></person-group>. <article-title>Transcriptional E2F1/2/5/8 as Potential Targets and Transcriptional E2F3/6/7 as New Biomarkers for the Prognosis of Human Lung Carcinoma</article-title>. <source>Aging (Albany NY)</source> (<year>2018</year>) <volume>10</volume>:<fpage>973</fpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.101441</pub-id>
<pub-id pub-id-type="pmid">29754146</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name></person-group>. <article-title>Bioinformatic Exploration of OLFML2B Overexpression in Gastric Cancer Base on Multiple Analyzing Tools</article-title>. <source>BMC Cancer</source> (<year>2019</year>) <volume>19</volume>:<fpage>227</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-019-5406-x</pub-id>
<pub-id pub-id-type="pmid">30866865</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Ni</surname><given-names>Sj</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Hedgehog Interacting Protein 1 is a Prognostic Marker and Suppresses Cell Metastasis in Gastric Cancer</article-title>. <source>J Cancer</source> (<year>2018</year>) <volume>9</volume>:<fpage>4642</fpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.27686</pub-id>
<pub-id pub-id-type="pmid">30588248</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pusapati</surname><given-names>RV</given-names></name><name><surname>Weaks</surname><given-names>RL</given-names></name><name><surname>Rounbehler</surname><given-names>RJ</given-names></name><name><surname>McArthur</surname><given-names>MJ</given-names></name><name><surname>Johnson</surname><given-names>DG</given-names></name></person-group>. <article-title>E2F2 Suppresses Myc-Induced Proliferation and Tumorigenesis</article-title>. <source>Mol Carcinog</source> (<year>2010</year>) <volume>49</volume>:<page-range>152–6</page-range>. doi: <pub-id pub-id-type="doi">10.1002/mc.20584</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimond</surname><given-names>M</given-names></name></person-group>. <article-title>Specific Tumor Suppressor Function for E2F2 in Myc-Induced T Cell Lymphomagenesis</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>:<page-range>15400–5</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0706307104</pub-id>
</mixed-citation>
    </ref>
    <ref id="B51">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>LN</given-names></name><name><surname>Rakijas</surname><given-names>JB</given-names></name><name><surname>Pandit</surname><given-names>SK</given-names></name><name><surname>Westendorp</surname><given-names>B</given-names></name><name><surname>Leone</surname><given-names>G</given-names></name></person-group>. <article-title>E2f8 Mediates Tumor Suppression in Postnatal Liver Development</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>:<fpage>2955</fpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI85506</pub-id>
<pub-id pub-id-type="pmid">27454291</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
